Pierre Fabre & NERLYNX commercialisation | Nerlynx
Pierre Fabre pens oncology pact with atomic energy spinout | Fierce Biotech
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
Puma regains China rights to Nerlynx and amends deal with Fabre
Puma regains China rights to Nerlynx and amends deal with Fabre
Will Puma Biotechnology Break Out of Its Rut in 2020? | The Motley Fool
Pierre Fabre amends license agreement with Puma Biotechnology - European Biotechnology
Partners of the Pierre Fabre Group: from health to beauty
Puma regains China rights to Nerlynx and amends deal with Fabre
THE FACES OF BREAST CANCER
CONTROL study results show improved tolerability of NERLYNX® (neratinib) with all the investigated diarrhoea prophylaxis strategies
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
CANbridge Pharmaceuticals and Puma Biotechnology Agree to Terminate NERLYNX® License Agreement and Settle Arbitration | Business Wire
Puma Bio: Sifting Through The Q4 Earnings Report (NASDAQ:PBYI) | Seeking Alpha
Puma Bio: A Contrarian Investment That Requires Patience (NASDAQ:PBYI) | Seeking Alpha
Accord entre Pierre Fabre et Puma Biotechnology
Fight against cancer : our therapeutic responses | Pierre Fabre
Fight against cancer : our therapeutic responses | Pierre Fabre
Puma regains China rights to Nerlynx and amends deal with Fabre
Blue March: Pierre Fabre supports colorectal cancer awareness month
Disappointing Nerlynx sales shows Pierre Fabre timing is everything | Evaluate
Puma Biotechnology: Finding Bullish Indications At The End Of 2019 (NASDAQ:PBYI) | Seeking Alpha
Partners of the Pierre Fabre Group: from health to beauty
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in
Puma Biotechnology, Pierre Fabre enter into Exclusive License Agreement
Puma Biotech's (PBYI) Nerlynx Aids Top Line, Overdependence a Woe
Puma and CANBridge cancel licensing deal for $20m
CONTROL study results show improved tolerability of NERLYNX® (neratinib) with all the investigated diarrhoea prophylaxis strategies | Pierre Fabre Pharma Norden AB
